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Abstract 
Functional Gly482Ser (rs8192678) and G/C (rs4253778) polymorphisms in 
the Peroxisome proliferator-activated receptor gamma coactivator1 
(PPARGC1A) and Peroxisome proliferator-activated receptor alpha (PPARα) 
genes, respectively, have been associated with mRNA and protein activity. 
The aim of this study was to determine their frequency distribution among 155 
Israeli athletes (endurance athletes and sprinters) and 240 healthy controls. 
Results showed that there was a significant difference in PPARGC1A 
Ser482Gly polymorphism genotype frequencies between endurance athletes 
and sprinters (P=0.005) as well as between endurance athletes and controls 
(p=0.0003). However, the sprinters' genotype and allele frequencies were 
similar to that of the control group. A significantly lower proportion of 
PPARGC1A Ser482 allele (0.25) was noted for the endurance athletes 
compared to controls (0.43, p=0.0001). Endurance athletes showed a trend of 
a higher yet a not significant proportion of the PPARα GG genotype compared 
to sprinters (p=0.051). As we compared between the subgroups of top-level 
endurance athletes and top-level sprinters, as well as between those of top-
level and national-level endurance athletes, we reached more prominent 
results. In conclusion, our data indicate that a lower frequency of the Ser482 
allele and possibly a higher frequency of the GG genotype are associated with 
increased endurance performance ability. 
 
Keywords: Genetics, aerobic performance, anaerobic performance, 
metabolism 
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Introduction 
Elite athletic performance is influenced, at least partly, by genetic components 
(MacArthur & North, 2005; Rankinen et al., 2006). However, while human elite 
performance phenotypes are highly polygenic, it is still unknown whether 
different genetic elements play a role in an athlete's talent for a specific type 
of sport (Amir et al., 2007).   
Peroxisome proliferator-activated receptor gamma coactivator1α 
(PPARGC1A) is a transcription coactivator that probably plays a role in a wide 
variety of biological responses, including mitochondrial biogenesis (Liang & 
Ward, 2006; Gonzalez-freire et al., 2008). PPARGC1A controls glucose 
transportation and lipid and glucose oxidation through the regulation of 
peroxisome proliferator-activated receptor alpha (PPARα) (Attie & 
Kendziorski, 2003). PPARGC1A and PPARα are expressed at high levels in 
tissues that catabolize fatty acids, notably those in the liver, skeletal muscle, 
and myocardium (Braissant et al., 1996; Liang & Ward, 2006). In humans, the 
PPARGC1A and the PPARα genes regulate the expression of genes 
encoding several key enzymes involved in fatty acid oxidation (Ahmetov et al., 
2006) and controlling oxidative phosphorilation (Lucia et al., 2005). Endurance 
training increases PPARGC1A mRNA levels (Tunstall et al., 2002; Pilegaard 
et al., 2003; Short et al., 2003; Norrbom et al., 2004;  Mathai et al., 2008), and 
thus, may enhance skeletal muscle oxidative capacity by PPARα regulation of 
gene expression (Lin et al., 2002; Russell et al., 2003).  
  Based on the premise that PPARGC1A Gly482Ser and PPARα G/C 
Single Nucleotide Polymorphisms (SNPs) are functional and therefore could 
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affect mRNA expression and/or protein levels, they have received recent 
attention in the medical literature. The Ser482 allele of the PPARGC1A gene 
was previously associated with type 2 diabetes (Ek et al., 2001; Hara et al., 
2002), whereas the Gly482 allele has been associated with beneficial effects 
such as alteration of lipid oxidation and early insulin secretion (Muller et al., 
2003). Furthermore, the C allele in the G/C polymorphism of the PPARα gene 
is thought to be associated with higher plasma lipid levels (Flavell et al., 
2000), cardiac growth (Jamshidi et al., 2002), and increasing risk of coronary 
artery disease (Flavell et al., 2002).  
  Only a few studies have tested the plausible effect of PPARGC1A and 
PPARα on athletic performance. Ahmetov et al. (2006) suggested that elite 
aerobic performance is affected by the G allele of the PPARα intron 7 G/C 
polymorphism. Lucia et al. (2005) reported an association between elite 
athletic performance and a common variant in the PPARGC1A gene 
(Gly482Ser), in which the frequency of the PPARGC1A minor Ser482 allele 
was lower in elite endurance athletes compared to unfit controls. However, a 
lack of association was noted between Vo2max and the Gly482Ser 
polymorphism in the German and Dutch populations (Stumvoll et al., 2004), 
as well as in the Northern Chinese population (He et al., 2008).  
The purpose of this study was to analyze the frequency distribution of 
PPARGC1A Gly482Ser (rs8192678) and PPARα G/C (rs4253778) 
polymorphisms in athletic and non-athletic Israeli populations. Another goal of 
this work was to compare within the athletic population the frequency 
distribution of the above SNPs between elite athletes of sports with different 
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demands (endurance vs. sprinters) and competitive levels (top-level vs. 
national level).  
 
Material and methods    
Subjects: One hundred and fifty-five athletes (119 men and 36 women, 
age=35.9+12.2 yrs) volunteered to participate in the study. Athletes were 
included in the study sample only if they had participated in 
national/international track and field championships. The control group 
consisted of 240 non-athletic Israeli healthy individuals that were randomly 
assigned from the Israeli population. Controls were not engaged in physical 
activity on a regular basis. Athletes were divided into two groups: 1) 
Endurance-type group that included 74 long distance runners, whose main 
event was the 10000m run or the marathon, and 2) Sprint-type group that 
included 81 sprinters whose main event was the 100-200m dash. According to 
their individual best performance, athletes within each group were further 
divided into two subgroups: top-level (those who had represented Israel in a 
world track and field championship or in the Olympic Games) and national 
level athletes. All subjects, athletes and non-athletes, were Israeli 
Caucasians, with an equivalent ratio of non-Ashkenazi and Ashkenazi descent 
in each group (2:1). (subjects' genotype characteristics are presented in Table 
1).  
The study was approved by the Helsinki Committee of the Hillel Yaffe 
Medical Center, Hadera, Israel, according to the Declaration of Helsinki. A 
written informed consent was obtained from each participant.  
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Genotyping 
Genomic DNA was extracted from peripheral EDTA treated anit-coagulated 
blood using a standard protocol (Sambrook et al., 1989). Genotyping of the 
PPARGC1A Gly482Ser (G/A) (rs8192678) and PPARα G/C (rs4253778) 
polymorphisms was performed using polymerase chain reaction (PCR) 
according to the methods of Kunej et al. (2004) and Jamshidi et al. (2002), 
respectively. The resulting PCR products were genotyped (in the Genetics 
and Molecular Biology Laboratory of the Zinman College of Physical 
Education and Sport Sciences at the Wingate Institute, Netanya, Israel) by 
restriction fragment length polymorphism (RFLP). Briefly, the Gly482Ser 
polymorphism was amplified using PCR primers F - 5' 
TAAAGATGTCTCCTCTGATT '3 and R - 5' 
GGAGACACATTGAACAATGAATAGGATTG '3. The amplified fragment 
subsequently underwent digestion by HPAΙΙ (New England Biolabs, Beverly, 
MA, USA). This method yields a 378-bp fragment in the presence of the 
Ser482 allele, and 209 and 169 bp in the presence of the Gly482 allele. The 
PPARα G/C polymorphism in intron 7 was amplified using PCR primers F- 5' 
ACAATCACTCCTTAAATATGGTGG '3 and R- 5' 
AAGTAGGGACAGACAGGACCAGTA '3. The amplified fragment 
subsequently underwent digestion by Taq Ι (New England Biolabs, Beverly, 
MA, USA). This method yields a 266-bp fragment in the presence of the C 
allele, and a 216 and 50 bp in the presence of the G allele. To ensure proper 
internal control, for each genotype analysis we used positive and negative 
controls from different DNA aliquots which were previously genotyped with the 
 7 
same method according to recent recommendations for replicating genotype-
phenotype association studies (Chanock et al., 2007). The RFLP results were 
scored by two experienced and independent investigators who were blind to 
subject data. 
Data analysis 
The SPSS statistical package, version 15.0, was used to perform all statistical 
evaluations (SPSS Inc., Chicago, IL, USA). Allele frequencies were 
determined by gene counting. A Χ2 test was used to confirm that the observed 
genotype frequencies were in Hardy-Weinberg equilibrium, and to compare 
the PPARGC1A Gly482Ser and the PPARα G/C alleles and genotype 
frequencies between athletes and control subjects as well as between 
genders and between athletes from different sports and competitive levels. 
The level of significance was set at P < 0.05. 
 
Results 
The results of the distribution of PPARGC1A Gly482Ser and the PPARα G/C 
polymorphisms genes in 155 Israeli athletes compared with 240 healthy 
sedentary Israeli individuals revealed that subjects' age, male/female 
genotype distribution, and allele frequencies did not differ by genotype, as 
summarized in Table 1. In addition, there were no differences across 
PPARGC1A and PPARα genotypes between Ashkenazi and non-Ashkenazi 
descendants. Our control population consisted of Israeli Caucasians, where 
the observed Ser482 allele frequency of the PPARGC1A was consistent with 
reports of Chinese (He et al., 2008) and Koreans (Kim et al., 2005), and 
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slightly lower than Danish (Ling et al., 2004), Germans (Stumvoll et al., 2004), 
British (Franks et al., 2003), and Spanish (Lucia et al., 2005) populations. The 
C/G allele frequencies in the present study were similar to those in the general 
population of Russia (Ahmetov et al., 2006). The PPARGC1A Gly482Ser and 
the PPARα G/C genotype and allele frequencies met Hardy-Weinberg 
expectations in the endurance athletes (P = 0.1 for Gly482Ser, and P = 0.64 
for G/C), sprinters (P = 0.98 for Gly482Ser, and P = 0.98 for G/C), and control 
group (P = 0.98 for Gly482Ser, and P = 0.96 for G/C). The PPARGC1A 
Gly482Ser allele frequency and genotype distribution of the whole cohort of 
athletes differed from the control group (Table 1). The endurance athletes' 
genotype distribution percentage of the PPARGC1A Gly482Ser genotype 
differed markedly from that of the sprinters, and the control group, as 
presented in Table 2. However, the sprinters' genotype distribution 
percentage was similar to that of the control group (Χ2 = 3.96, d.f=2, p=0.13). 
Allele frequency in the endurance group was significantly different than that in 
the controls (Table 2). Nevertheless, allele frequency of the endurance group 
and the sprinters did not reach significant difference (Χ2 = 3.4, d.f=1, p=0.07). 
We observed a significantly lower proportion of Ser/Ser genotype among 
endurance athletes (0%) in comparison with the sprinters (17%, Χ2 = 5.82, 
d.f=1, p=0.016) and controls (16.3%, Χ2 = 6.34, d.f=1, p=0.012). The 
endurance athletes' genotype distribution percentage and allele frequencies of 
the PPARα G/C polymorphism did not differ from those of sprinters and 
controls, as shown in Table 2. However, a trend of a higher yet not a 
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significant proportion of the PPARα GG genotype was noted in endurance 
athletes (10%) compared with the sprinters (1%, Χ2 = 3.8, d.f=1, p=0.051). 
As shown in Table 4, the comparisons of genotype and allele 
frequencies for PPARGC1A revealed significant differences between the 
subgroups of top-level endurance athletes vs. top-level sprinters, as well as 
between top-level vs. national level endurance athletes. However, no difference 
in genotype distribution (Χ2 = 1.5, d.f=2, P=0.47) and allele frequencies (Χ2 = 
1.56, d.f=1, P=0.21) was noted between top-level and national level sprinters. 
PPARα GG genotype was more prevalent in the group of top-level endurance 
athletes (20%) than in the national level endurance athletes, although it did not 
reach statistical significance (Χ2 = 3.46, d.f=1, P=0.06).  
 
Discussion 
Our main findings are the low levels of PPARGC1A Ser482 allele, and the 
PPARGC1A Ser/Ser genotype among the Israeli endurance athletes. These 
findings are interesting and fairly unique, given the fact that this is one of the 
few studies comparing between sedentary controls and "extreme" phenotypes 
(endurance athletes and sprinters).  
Our study demonstrated a significant difference in the PPARGC1A 
Ser482Ser genotype between the group of endurance athletes and sprinters. 
Thus, a trade off between endurance and sprint performance traits seems 
plausible, since none of the elite endurance athletes harbored the Ser482Ser 
genotype, as opposed to 13% of the elite sprinters. Interestingly, as we 
decided to compare the frequency distribution of the above SNPs between 
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elite athletes of sports with different demands (endurance vs. sprinters) and 
competitive levels (top-level vs. national level), our results were more 
significant, indicating that the Gly482Ser SNP may be an important genetic 
factor in determining top-level aerobic performance. 
 It seems that PPARGC1A and PPARα mRNA and/or protein increase 
fatty acid metabolism, and thus play an important role in the control of fatty 
acid oxidation. PPARGC1A and PPARα mRNA and/or protein are expressed 
in high levels mainly in cells with abundant mitochondria and, consequently, 
with a predominant oxidative metabolism as during endurance performance 
(Liang & Ward, 2006) PPARGC1A modulates muscle oxidative capacity, 
primarily via the coactivation of nuclear respiratory factors (NRF-1 and NRF-
2), cytochrome-c oxidase 4 (COX4), mitochondrial transcription factor A 
(Tfam), and other proteins required for mitochondrial function which induce 
mitochondrial biogenesis (Wang et al., 2004).  
 Connecting these data with muscle function, Pilegaard et al. (2003) and 
recently Mathai et al. (2008) demonstrated that a single bout of prolonged 
endurance exercise induces a marked increase in transcription and mRNA 
content of PPARGC1A in skeletal muscle, which peaks within the first 2 h 
after exercise. Studies also showed that both animals (Baar et al., 2002; 
Terada et al., 2002; Terada & Tabata, 2004;) and humans (Russell et al., 
2003; Short et al., 2003; Norrbom et al., 2004) increase PPARGC1A mRNA 
levels as a response to chronic endurance exercise training, whereas 
PPARGC1A protein controls muscle plasticity, suppresses a broad 
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inflammatory response, and mediates the beneficial effects of exercise 
(reviewed by Handschin & Spiegelman, 2008).  
  The expression level of PPARα has been shown to be higher in type І 
(slow twitch) than in type ІІ (fast twitch) muscle fibers, when homozygotes for 
the G allele of the PPARα G/C polymorphism had a significantly higher 
percentage of slow-twitch fibers (Ahmetov et al., 2006). These accumulating 
findings are notable since they suggest that the expression levels of 
PPARGC1A and PPARα may be genotype-dependent. Keeping in mind that 
the muscle phenotype of endurance runners is mainly composed of type I 
muscle fibers with a high mitochondrial density and size enables their reliance 
mainly on mitochondrial oxidation of free fatty acids and carbohydrates. 
Therefore, we assume that the expressed levels of PPARGC1A and PPARα 
will influence ability of the muscles to achieve the required phenotype as 
previosly suggested (Russell et al., 2003; Short et al., 2003; Norrbom et al., 
2004). 
 Both PPARα intron 7 G/C and PPARGC1A Gly482Ser SNPs studied in 
the present study have been associated with improved aerobic performance 
(Ahmetov et al., 2006; Lucia et al., 2005). In addition, the present study is in 
agreement with those previous reports (Lucia et al., 2005; Ahmetov et al., 
2006) regarding the positive role of the Gly482Ser and the G/C SNPs with 
endurance performance, and disagrees with others (Stumvoll et al., 2004; He 
et al., 2008). The discrepancy between the present study and those of 
Stumvoll et al., (2004) and He et al., (2008) may be due to different study 
populations and methods. .  
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 In conclusion, our data indicate that a lower frequency of the 
PPARGC1A Ser482 allele and possibly a higher frequency of the PPARα GG 
genotype are associated with top-level endurance athletes, and further 
support the notion that increased PPARGC1A and PPARα mRNA and/or 
protein activity may be advantageous to the performance of endurance-type 
athletes. In addition, data suggest that the above SNPs may belong to a 
group of several genetic variations that influence top-level endurance 
performance 
Perspectives 
The process of talent identification could, in principle, be revolutionized by the 
discovery of genetic variants that strongly influence athletic performance 
(MacArthur & North, 2005), primarily at the top level. However, there is still no 
evidence that any of the genetic variants that were previously investigated 
have substantial value in the prediction of potential top-level athletes. One 
rationale for this study was the understanding of the importance and influence 
that genome factors such as PPARGC1A and PPARα have on athletic 
performance. It seems that further investigation is needed on top athletes at 
the Olympic level among different ethnic groups in order to clarify the potential 
role of both the Gly482Ser and the G/C polymorphisms in determining 
endurance and sprint ability.  
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Table 1. Genotype and allele frequencies of PPARGC1A Gly482Ser and PPARα G/C 
polymorphisms with gender and age. Values are absolute and relative frequencies (in 
parentheses). Χ2 and P values correspond to gender comparisons in genotype and 
allele frequencies. 
 
                                                   Genotype                                                                Allele frequencies 
                                                                                                                                   
 
PPARGC1A  n Gly/Gly Gly/Ser Ser/Ser Χ
2 
 P   Allele Gly482 Allele Ser482 Χ
2 
 P 
 Athletes           
All  155 72 (46) * 73 (47) * 10 (7) *   217 (0.70) $ 93 (0.30) $   
Male  119 58 (49) 55 (46) 6 (5) 1.18 0.55 171 (0.72) 67 (0.28) 1.31 0.25 
Female  36 14 (39) 18 (50) 4 (11)   46 (0.64) 26 (0.36)   
Age  34.9+12 34.9+12 36.9+12       
Controls           
All  240 79 (33) 117 (49) 44 (18)   275 (0.57) 205 (0.43)   
Male  170 60 (35) 78 (46) 32 (19) 1.57 0.45 198 (0.58) 142 (0.42) 0.3 0.58 
Female  70 19 (27) 39 (56) 12 (17)   77 (0.55) 63 (0.45)   
Age  26+3 25+3 27+3       
PPAR-α   GG GC CC     Allele G Allele C     
 Athletes           
All  155 8 (5) 43 (28) 104 (67)   59 (0.19) 251 (0.81)   
Male  119 7 (6) 34 (29) 78 (65) 0.22 0.9 48 (0.20) 190 (0.80) 0.57 0.45 
Female  36 1 (3) 9 (25) 26 (72)   11 (0.15) 61 (0.85)   
Age  34.9+12 34.9+12 36.9+12       
Controls           
All  240 10 (4) 67 (28) 163 (68)   87 (0.18) 393 (0.82)   
Male  170 8 (5) 48 (28) 114 (67) 0.11 0.95 64 (0.19) 276 (0.81) 0.38 0.54 
Female  70 2 (3) 19 (27) 49 (70)   23 (0.16) 117 (0.84)   
Age   26+3 25+3 27+3             
 
* Χ2 =14.3, d.f=2, P=0.0008 for genotype frequencies in athletes vs. controls 
$ Χ2 = 12.9, d.f=1, P=0.0003 for allele frequency in athletes vs. controls 
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Table 2. The PPARGC1A Gly482Ser and PPARα G/C genotype and allele frequencies 
in all groups 
 
                                                                                      
                                                                                Genotype                                          Allele frequencies 
                                                                                                                    
PPARGC1A Athlete groups n Gly/Gly Gly/Ser Ser/Ser  Allele Gly482 Allele Ser482 
        
 Endurance  74 37 (50)*† 37 (50)*† 0 (0)*†  111 (0.75) $ 37 (0.25) $  
 Sprinters 81 35 (43) 36 (44) 10 (13) 106 (0.65) 56 (0.35) 
 Control 240 79 (33) 117 (49) 44 (18) 275 (0.57) 205 (0.43) 
PPAR-α  Athlete groups   GG GC CC Allele G Allele C 
 Endurance  74 7 (10) 21 (28) 46(62) 35 (0.24) 113 (0.76) 
 Sprinters 81 1 (1) 22 (27) 58 (72) 24 (0.15) 138 (0.85) 
 Control 240 10 (4) 67 (28) 163 (68) 87 (0.18) 393 (0.82) 
 
* Χ2 = 16.04, d.f=2, p=0.0003 for genotype frequencies in endurance athletes vs. 
controls  
† Χ2 = 10.6, d.f=2, p=0.005 for genotype frequencies in endurance athletes vs. 
sprinters 
$ Χ2 = 14.48, d.f=1, p=0.0001 for allele frequency in endurance athletes vs. 
controls 
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Table 3. The PPARGC1A Gly482Ser and PPARα G/C genotype and allele frequencies 
in athletes divided by subgroups  
 
                                                                                                  Genotype                                      Allele frequencies 
                                                                                                                                                    
  
Athlete 
groups 
Competitive 
level n Gly/Gly Gly/Ser Ser/Ser Allele Gly482 Allele Ser482 
 Endurance Top-level 20 15  (75) & 5  (25) &  0 (0) & 35 (0.87) ‡ 5 (0.13) ‡ 
PPARGC1A  National level 54 22 (41) 32 (69) 0 (0) 72 (0.67) 36 (0.33) 
 Sprinters Top-level 26 8 (31) 14 (54) 4 (15) 30 (0.58) 22 (0.42) 
  National level 55 27 (49) 22 (40) 6 (11) 76 (0.69) 34 (0.31) 
        GG GC CC Allele G Allele C 
 Endurance Top-level 20 4 (20) 4 (20) 12 (60) 12 (0.30) 28 (0.70) 
PPAR-α  National level 54 3 (6) 17 (31) 34 (63) 23 (0.21) 85 (0.79) 
 Sprinters Top-level 26 0 (0) 11 (42) 15 (58) 11 (0.21) 41 (0.79) 
    National level 55 1 (2) 11 (20) 43 (78) 13 (0.12) 97 (0.88) 
 
& Χ2 = 5.55, d.f=1, P=0.018 for genotype frequencies in top-level vs. national level 
endurance athletes 
‡ Χ2 = 5.38, d.f=1, P=0.02 for allele frequencies in top-level vs. national level 
endurance athletes 
 
 
 
